Previous 10 | Next 10 |
2023-09-06 10:00:10 ET More on Health Care Select Sector SPDR Seeking Alpha’s Quant Rating on Health Care Select Sector SPDR Dividend scorecard for Health Care Select Sector SPDR Stagflation Playbook: Short Tech (QQQ/ARKK) And Long Healthcare ( XLV ) ...
2023-09-06 08:50:35 ET System1 ( SST ) +23% Confirms Receipt of Indication of Interest for Total Security From Just Develop It. Journey Medical ( DERM ) +19% Enters into an Exclusive License Agreement with Maruho Co., Ltd. for Qbrexz in South Korea and Other As...
2023-08-24 10:00:34 ET Gainers: CollPlant Biotechnologies ( CLGN ) +11% NeuBase Therapeutics ( NBSE ) +7% NeuroPace ( NPCE ) +7% Bionomics ( BNOX ) +6% Enhabit ( EHAB ) +16% Losers: NanoVibronix ( NAOV ) -15% ...
2023-08-24 08:40:38 ET Bruush Oral Care ( BRSH ) +62% . Hitek Global ( HKIT ) +19% . Guess? GES +16% on Q2 earnings release . Groupon ( GRPN ) +14% . Splunk SPLK +14% on Q2 earnings release . Eos Energy Enterprises ( EOSE ) ...
2023-08-03 10:16:24 ET Gainers: Bluejay Diagnostics ( BJDX ) +74% . Adamis Pharmaceuticals ( ADMP ) +59% . T2 Biosystems ( TTOO ) +47% . Community Health Systems ( CYH ) +18% . Cyclo Therapeutics ( CYTH ) +17% . Losers:...
2023-08-03 08:46:55 ET Traeger ( COOK ) +28% . NeuBase Therapeutics ( NBSE ) +21% . Upwork ( UPWK ) +17% Q2 earningas call release Biophytis ( BPTS ) +16% . Interactive Strength ( TRNR ) +16% Announces Distribution Partnershi...
PITTSBURGH, Aug. 03, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today anno...
PITTSBURGH, June 30, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced th...
New preclinical data validates that Stealth Editors™ are non-immunogenic, as featured in a poster presentation at the 28th American Peptide Symposium First non-human primate (NHP) study to successfully redose a gene editor without an immune response Ex vivo data sho...
PITTSBURGH, June 28, 2023 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing Stealth Editors™ to perform in vivo gene editing without triggering the immune system, today announced th...
News, Short Squeeze, Breakout and More Instantly...
NeuBase Therapeutics Inc. Company Name:
NBSE Stock Symbol:
NYSE Market:
NeuBase Therapeutics Inc. Website:
Usinas Siderurgicas De Minas Gerais S.A. ADR (Representing Pref Share Cl A) (USNZY) is expected to report $0 for Q2 2024 CREATD INC. (CRTD) is expected to report for Q1 2024 Bluegreen Vacations Holding Corporation - Class B (BVHBB) is expected to report for Q1 2024 Senstar Technologie...
Verbund AG ADR (OEZVY) is expected to report for Q1 2024 Rent the Runway Inc. (RENT) is expected to report $-6.56 for Q1 2025 Johnson Matthey plc ADR (JMPLY) is expected to report for Q4 2024 RVL Pharmaceuticals plc (RVLPQ) is expected to report for Q1 2024 Ciena Corporation (CIEN...
Macquarie Group Ltd ADR (MQBKY) is expected to report for Q4 2024 Hormel Foods Corporation (HRL) is expected to report $0.35 for Q2 2024 Howden Joinery Group Plc ADR (HWDJY) is expected to report for Q1 2024 Eiger BioPharmaceuticals Inc. (EIGRQ) is expected to report for Q1 2024 M...